Obesity Clinical Trial
— ARrOWOfficial title:
Adaptive Responses to Overfeeding and Weight Regain in Reduced Obese Individuals
To more effectively address the problem of weight regain following weight loss for obese individuals, this study will evaluate the underlying biology of the reduced obese state. In depth studies of appetite, energy expenditure, physical activity levels and fat metabolism will be completed in obese and reduced obese individuals; with the latter subdivided into those who have lost weight with diet alone or diet plus exercise. Individuals will be studied following a brief overfeeding period to better understand how differences in biological responses to overeating might be involved in promoting or protecting against weight gain.
| Status | Recruiting |
| Enrollment | 75 |
| Est. completion date | January 1, 2024 |
| Est. primary completion date | January 1, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 30 Years to 50 Years |
| Eligibility | Inclusion criteria. - BMI of 30-38 kg/m2 and weight stable over the previous 6 months. - Satisfied with current weight and not planning to lose weight at the time of enrollment (persons with obesity control group) -or- not satisfied with current weight and motivated to lose weight at the time of enrollment (reduced obese groups) - No more than 90 min or 3 bouts of planned physical activity/wk. - Pass a medical and physical screening performed by the study physician. - Reporting a habitual, regular sleep-wake cycle for the month preceding screening that involved going to bed between 2200 and 0100 h and getting up between 0600 and 0900 h with >7 h and <9.25 h in bed. - Live or work within 45 minutes of the CU-AMC (reduced obese groups only) (exceptions may be made at the discretion of the Study PI on a case by case basis for highly motivated subjects). - Own a smartphone (Android or Apple iOS). - For Females - Not currently pregnant or lactating - Not pregnant within the past 6 months - Not planning to become pregnant in the next 12 months; sexually active women of childbearing potential may be enrolled if they use a reliable means of contraception - Capable and willing to provide informed consent, understand exclusion criteria, and accept the randomized group assignment (reduced obese groups) Exclusion criteria. - Being considered unsafe to participate as determined by the study physician; - Taking medications affecting weight, triglycerides, or energy intake/energy expenditure in the last 3 months; - Having abnormal blood chemistry and/or hematology as deemed significant by the study physician; - Ever having a history of systemic, psychiatric, neurological disease, or drug and alcohol abuse; - History of cardiovascular disease, diabetes, uncontrolled hypertension, untreated thyroid, renal, hepatic diseases, dyslipidemia or any other medical condition affecting weight or lipid metabolism; - Score > 18 on Beck Depression Index (BDI) will require further assessment by the study physician to determine if it is appropriate for the subject to participate in the study; - Use of a continuous positive airway pressure (CPAP) device for the treatment of obstructive sleep apnea (OSA). A score of >10 on the Epworth sleepiness scale or >5 on the Pittsburgh Sleep Quality Index will require further assessment by the study physician to determine if it is appropriate for the subject to participate in the study; - Being positive for human immunodeficiency virus or hepatitis B or C; - History of surgical procedure for weight loss at any time (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve); - Being a smoker or having been a smoker in the previous 6 months; - Abnormal eating patterns identified by registered dietitian interview (dietary fat<15%, dietary fat>45%, dietary protein >30%); - Working night shifts; - Night eating syndrome (at least 25% of food intake is consumed after the evening meal and/or at least two episodes of nocturnal eating per week); - Traveling > 2 time zones 2 weeks prior to an inpatient CTRC study visit; - Currently participating in any formal weight loss or physical activity programs or clinical trials. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Colorado Hospital | Aurora | Colorado |
| Lead Sponsor | Collaborator |
|---|---|
| University of Colorado, Denver | University of Colorado, Boulder |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Change in fitness as measured by indirect calorimetry | Fitness will be measured using indirect calorimetry during a graded exercise test to volitional exhaustion | 30 minutes at baseline and 1 year following second diet condition; Reduced group will have an additional measurement at week 12 following weight loss period. | |
| Primary | Fat oxidation as a correlate of weight regain as measured by room calorimetry | Fat oxidation as a correlate of weight regain will be assessed in both reduced obese groups with room calorimetry on two occasions, once after 3 days of overfeeding and once after 3 days of an energy balanced diet. | 24 hour period on day 7 of two diet conditions - one overfed & one eucaloric condition; weeks 16 & 20 | |
| Secondary | Body weight per scale | Body weight will be measured via clinic scale. Change in body weight in response to the weight loss intervention | Baseline, after 12 week weight loss intervention and 1 year after the end of second study condition | |
| Secondary | Body Composition via DXA | Body composition will be measured via DXA, Change in body composition in response to the weight loss intervention | Baseline, after 12 week weight loss intervention and 1 year after the end of second study condition | |
| Secondary | Change in substrate utilization as measured by room calorimetry | Substrate utilization will be measured by room calorimetry (change = overfeeding diet condition - eucaloric diet condition) | 24 hour period, on day 7 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and week 16 & 20 for reduced groups | |
| Secondary | Change in nocturnal lipolysis as measured by use of stable isotope tracer | Lipolysis will be measured using stable isotope tracers (change = overfeeding diet condition - eucaloric diet condition) | 24 hour period, on day 7 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Change in total energy expenditure (TEE) as measured by room calorimetry | TEE will be measured by room calorimetry (change = overfeeding diet condition - eucaloric diet condition) | 24 hour period, on day 7 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Change in spontaneous physical activity (SPA) as measured by accelerometers | SPA will be measured using accelerometers (change = overfeeding diet condition - eucaloric diet condition) | 7 days, on days 4-10 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Change in spontaneous food intake measured with an ad libitum diet | Spontaneous food intake will be measured during a 3 day ad libitum diet (change = overfeeding diet condition - eucaloric diet condition) | 3 days - on days 8-10 - of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Change in hunger and satiety using Visual Analog Scale | Hunger and satiety will be measured using visual analog scales (change = overfeeding diet condition - eucaloric diet condition) | 3 days - on days 8-10 - of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Change in 24h hormone and metabolite profiles as measured by assay of plasma samples | 24h hormone and metabolite profiles will be assayed in plasma samples obtained during inpatient study visits (change = overfeeding diet condition - eucaloric diet condition) | 3 days - days 8-10 - of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Lipolysis as a correlate of weight regain as measured by stable isotope tracer | Lipolysis as a correlate of weight regain will be assessed in both reduced obese groups with a stable isotope tracer on two occasions, once after 3 days of overfeeding and once after 3 days of an energy balanced diet. | 24 period, on day 7 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Total energy expenditure (TEE) as a correlate of weight regain as measured by room calorimetry | TEE as a correlate of weight regain will be assessed in both reduced obese groups with room calorimetry on two occasions, once after 3 days of overfeeding and once after 3 days of an energy balanced diet. | 24 period, on day 7 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Spontaneous physical activity (SPA) as a correlate of weight regain as measured by accelerometers | SPA as a correlate of weight regain will be assessed in both reduced obese groups with accelerometers on two occasions, once after 3 days of overfeeding and once after 3 days of an energy balanced diet. | 7 days, on days 4-10 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Spontaneous food intake as a correlate of weight regain as measured with an ad libitum diet | SPA as a correlate of weight regain will be assessed in both reduced obese groups with an ad libitum diet on two occasions, once after 3 days of overfeeding and once after 3 days of an energy balanced diet. | 3 days - days 8-10 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | 24h hormone and metabolite profiles as a correlate of weight regain as measured by assay of plasma samples | 24h hormone and metabolite profiles as a correlate of weight regain will be assessed in both reduced obese groups by assay of plasma samples on two occasions, once after 3 days of overfeeding and once after 3 days of an energy balanced diet. | 24 period, on day 7 of two diet conditions - eucaloric and overfed; week 1 and 4 for controls and weeks 16 and 20 for reduced | |
| Secondary | Total daily energy expenditure as a correlate of weight regain as measured by doubly labeled water | Total daily energy expenditure as a correlate of weight regain will be measured in both reduced obese groups using doubly labeled water after the second diet condition intervention | two 1 week periods at 1 month and 1 year after second diet condition; week 8 and week 56 for controls and week 24 and week 72 for reduced | |
| Secondary | Correlates of Weight Regain as measured by questionnaire | Correlates of weight regain will be assessed in both reduced obese groups with questionnaires periodically over the intervention and follow-up period | 30 minutes at baseline and every 8 weeks for 1 year following second diet condition; weeks 12, 20, 28, 36, 44, 52 for controls and weeks 28, 36, 44, 52, 60, 68, for reduced. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |